## Break Out Room Locations

### Level 1 - ISAM Breakout Rooms

- **Hall E** (M001)
- **Hall G** (C003)
- **Hall F**

### Level 3 - ISAM Breakout Rooms

- **Hall B** (M031)
- **Hall C** (C031)
- **Hall D** (C033)

## Workshop Program

<table>
<thead>
<tr>
<th>Time</th>
<th>Workshop</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00 - 17:00</td>
<td>W1: SBIRT for Primary Care Doctors</td>
<td>Robert Ali, Australia; Mansour Shawky, UAE; Nael Hasan, UAE</td>
</tr>
<tr>
<td></td>
<td>W2: Pharmacology and Toxicology of Classical Drugs of Abuse and New Psychoactive Substances</td>
<td>Marilyn Huestis, USA; Hans Maurer, Germany; Markus Meyer, Germany; Abuelgasim Elrasheed, UAE</td>
</tr>
<tr>
<td></td>
<td>W3: Matrix Program</td>
<td>Richard Rawson, USA; Alyazia Al-Khaja, UAE; Mariam Al-Ateeqi, UAE</td>
</tr>
<tr>
<td></td>
<td>W4: Family Therapy in Addiction</td>
<td>Jenene Case Pease, USA</td>
</tr>
<tr>
<td></td>
<td>W5: ISAM Fundamentals: Training the Educators/Teachers in Addiction Medicine</td>
<td>Barbara Broers, Switzerland; Cor de Jong, The Netherlands</td>
</tr>
</tbody>
</table>

**Registration**

- **Opening Ceremony - (Emirates Palace)**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>19:30 - 20:30</td>
<td>Opening Ceremony</td>
</tr>
</tbody>
</table>

**URL:** [www.isam2017abudhabi.ae](http://www.isam2017abudhabi.ae)
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
<th>Chair(s)</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30 - 09:15</td>
<td>Plenary Session 1 - Modern, Effective Care for Substance Use Disorders: Findings from the 2016 US Surgeon General's Report</td>
<td>Hall A</td>
<td>Hamad Al Ghaferi, UAE</td>
<td>Thomas McLellan, USA</td>
</tr>
<tr>
<td>09:15 - 10:00</td>
<td>Plenary Session 2 - Addiction as a Brain Disease A Strategic Challenge</td>
<td>Hall A</td>
<td>Ahmed Okasha, Egypt</td>
<td>Olivera Bogunovic, USA</td>
</tr>
<tr>
<td>10:00 - 10:15</td>
<td>Coffee Break - Poster Session</td>
<td>Hall A</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### SCIENTIFIC PROGRAM

**Hall A**

- **S1:** Addiction Medicine Across the Globe
  - Chair: Hamad Al Ghaferi, UAE
  - Co-Chair: Gregory Bunt, USA
  - **Addiction Medicine Across the Globe: The Role of ISAM**
    - Gregory Bunt, USA
  - **Tramadol Misuse and Dependence: Pharmacology and Clinical Effects**
    - Karen Miotto, USA

- **S2:** Neuroscience-based Approaches to Assessment, Prognosis and Treatment of Substance Use Disorders
  - Chair: TBC
  - Co-Chair: Hamed Ekhtiari, USA
  - **Neuroimaging Findings in Youth: Does Teenage Substance Use Harm the Brain?**
    - Susan Tapert, USA

- **S3:** Pharmacotherapy of Addiction
  - Chair: Kathleen Brady, USA
  - Co-Chair: Louise Haynes, USA
  - **Pharmacotherapy for Alcohol Dependence**
    - Hannu Alho, Finland
  - **Pharmacotherapy for Stimulant Dependence**
    - Ahmed Elkashef, UAE

- **S4:** Harvard Mcclean Symposium: Substance Use Disorders in Women Across Cultures
  - Chair: Doaa Nader Radwan, UAE
  - Co-Chair: Olivia Bogunovic, USA
  - **Pharmacotherapy for Opioid Dependence**
    - Walter Ling, USA
  - **Future Directions - New Modalities in Treatment**
    - Olivia Bogunovic, USA

**Hall B**

- **ME1:** Primary Health Care Role in Addiction
  - Chair: Robert Ali, Australia

- **ME2:** Strengthening Addiction Medicine: Opportunities in Southeast Asia, South Africa and Vietnam
  - Igor Koutsenok, USA
  - Apinun Aramrattana, Thailand
  - Hoang Huy Vu, Vietnam
  - Beverly Cummings, South Africa
  - Nadine E. Rogers, Vietnam

**Hall C**

- **S5:** Tramadol Misuse and Dependence in the Middle East: New Knowledge
  - Chair: Ahmed Okasha, Egypt
  - Co-Chair: Richard A. Rawson, USA
  - **Pharmacotherapy for Stimulant Dependence**
    - Ahmed Elkashef, UAE

- **S4:** Substance Use Disorders in Women in United States and Europe
  - Chair: Doaa Nader Radwan, UAE
  - **Demographics and Clinical Characteristics of Tramadol-Using Patients Seeking Treatment in Cairo University Hospital, Egypt**
    - Mohamed Abdel Fattah Khalil, Egypt
  - **Psychological and Physical Hazards of Tramadol**
    - Karen Miotto, USA

**Hall D**

- **S4:** Substance Use Disorders in Women in the Middle East
  - Chair: Doaa Nader Radwan, UAE
  - **Demographics and Clinical Characteristics of Tramadol-Using Patients Seeking Treatment in Cairo University Hospital, Egypt**
    - Mohamed Abdel Fattah Khalil, Egypt
  - **Psychological and Physical Hazards of Tramadol**
    - Karen Miotto, USA

**Hall E**

- **S5:** Tramadol Misuse and Dependence in the Middle East: New Knowledge
  - Chair: Ahmed Okasha, Egypt
  - Co-Chair: Richard A. Rawson, USA

**Hall F**

- **S5:** Tramadol Misuse and Dependence: Pharmacology and Clinical Effects
  - Karen Miotto, USA

**Hall G**

- **ME1:** Primary Health Care Role in Addiction
  - Chair: Robert Ali, Australia

- **ME2:** Strengthening Addiction Medicine: Opportunities in Southeast Asia, South Africa and Vietnam
  - Igor Koutsenok, USA
  - Apinun Aramrattana, Thailand
  - Hoang Huy Vu, Vietnam
  - Beverly Cummings, South Africa
  - Nadine E. Rogers, Vietnam

**Exhibition**

- **Hall A**
  - **Hall B**
  - **Hall C**
  - **Hall D**
  - **Hall E**
  - **Hall F**
  - **Hall G**

**Registration**

- 08:30 - 09:15
- 09:15 - 10:00
- 10:00 - 10:15

**Thursday, 26 October, 2017**

- **Plenary Session 1**
  - 08:30 - 09:15
  - Thomas McLellan, USA

- **Plenary Session 2**
  - 09:15 - 10:00
  - Ahmed Okasha, Egypt

**Future Directions - New Modalities in Treatment**

- Olivia Bogunovic, USA

**Bridging the Cultural Divide: When Western Psychiatry meets Middle Eastern Values**

- Rima Saad, USA

**Patient characteristics presented for treatment at the National Rehabilitation Center, Abu Dhabi, UAE**

- Nael Moustafa Hassan Mohamed, UAE

**Using Transcranial Electrical Stimulation to Improve Treatment Outcomes in Substance Use Disorder**

- Hamed Ekhtiari, USA

**Adult Attention Deficit Hyperactivity Disorder Among Adult Male Patients with Tramadol Dependence: A Comparative Study**

- Samir Abou El Magd, Egypt
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:15 - 12:45</td>
<td>Plenary Session 3 - Addiction in the Middle East: Status Update - Hamad Al Ghaferi, UAE</td>
<td>Hall A</td>
</tr>
<tr>
<td>12:45 - 13:15</td>
<td>Plenary Session 4 - Mental Health Issues in the UAE - Rafia Ghubash, UAE</td>
<td>Hall A</td>
</tr>
<tr>
<td>13:15 - 14:15</td>
<td>Lunch Break - Poster Session</td>
<td></td>
</tr>
<tr>
<td>12:15 - 13:15</td>
<td>S9: Khat Use in Saudi Arabia Between Co-Morbidity and Economic Elasticity</td>
<td>Hall A</td>
</tr>
<tr>
<td></td>
<td>Chair: Rashad Alsanosy, KSA Co-Chair: Mohammed Al Jneibi, UAE</td>
<td></td>
</tr>
<tr>
<td>13:15 - 14:15</td>
<td>EUROPAD Meeting (by invitation only)</td>
<td>Hall F</td>
</tr>
<tr>
<td>14:15 - 16:15</td>
<td>ISAM Textbook Editors Meeting (by invitation only)</td>
<td>Hall G</td>
</tr>
<tr>
<td>16:15 - 17:15</td>
<td>Plenary Session 5 - Stress and Addictions: Neurobiologic Interface - Kathleen Brady, USA</td>
<td>Hall A</td>
</tr>
<tr>
<td></td>
<td>Chair: Ahmed El Khasef, UAE</td>
<td></td>
</tr>
</tbody>
</table>

### Scientific Program

- **Hall A**
  - **S6:** Indivior Symposium: Desired Outcomes of Treating Opioid Addicted Patients
    - Chair: Ahmed Elkashef, UAE
  - **S7:** Recent Research Findings on Addiction Regional Challenges and Psychological Correlates
    - Chair: Mustafa Al'Absi, USA Co-Chair: Ossama Osman, UAE
  - **S8:** Neurocognitive Functions & Drug Addiction Treatment: Targets, Predictors and Interventions
    - Chair: Alex Baldacchino, UK Co-Chair: Hamed Ekhtiari, USA
  - **S9:** Khat Use in Saudi Arabia Between Co-Morbidity and Economic Elasticity
    - Chair: Rashad Alsanosy, KSA Co-Chair: Mohammed Al Jneibi, UAE

- **Hall B**
  - Desired Outcomes & Cost Implications of Detox vs. Maintenance Treatment of Opioid Addiction. How can we achieve more for less?
    - Rok Hren, Slovenia
  - Neurobiologic Basis of Opioid Addiction - The Clinical Importance of Receptor blockade
    - Roberto Ciccocioppo, Italy
  - The Impact of Cannabis Addiction on Human Emotions Processing: BOLD-RMRI Study
    - Manel Ben Fredj
  - The Influence of Psychiatric Co-Morbidity on the Effects of Brief Intervention to Reduce Khat Use
    - Victoria Mutis, Kenya
  - Blunted Neural Valuation Signals in Young Binge Drinkers
    - Douglas Steele, UK
  - University of Vermont, Reflection on Latest Trends in Research and Training in the Region
    - Richard Rawson, USA
  - University of Vermont, Trialing Neurocognitive Interventions During Detoxification
    - Dan Lubman, Australia

- **Hall C**
  - The Influence of Psychiatric Co-Morbidity on the Effects of Brief Intervention to Reduce Khat Use
    - Victoria Mutis, Kenya
  - Impulsivity and Compulsivity in Opioid Dependence
    - Serenella Tolomeo, USA
  - The Impact of Cannabis Addiction on Human Emotions Processing: BOLD-RMRI Study
    - Manel Ben Fredj
  - University of Vermont, Reflection on Latest Trends in Research and Training in the Region
    - Richard Rawson, USA
  - University of Vermont, Trialing Neurocognitive Interventions During Detoxification
    - Dan Lubman, Australia

- **Hall D**
  - Protection, Anxiety and Stress Among Khat Chavers in Jazan Region, Kingdom of Saudi Arabia
    - Khat Use
    - Rashad Alsanosy, KSA
  - Depression, Anxiety and Stress Among Khat Chavers in Jazan Region, Kingdom of Saudi Arabia
    - Khat Use
    - Rashad Alsanosy, KSA
  - Effect of Khat Use on Antipsychotic Medications Among Schizophrenia Patients at Jazan Region, Kingdom of Saudi Arabia
    - Tahir Hakami, KSA
  - Measuring the Price of Elasticity of Khat Demand: A Cross-Sectional Study on Jazan Province
    - Maged El-Setouhy, KSA
  - Measuring the Income Elasticity of Khat Demand: A Cross-Sectional Study on Jazan Province
    - Kamaludin Sheikh, KSA

- **Hall E**
  - The Influence of Psychiatric Co-Morbidity on the Effects of Brief Intervention to Reduce Khat Use
    - Victoria Mutis, Kenya
  - Impulsivity and Compulsivity in Opioid Dependence
    - Serenella Tolomeo, USA
  - The Impact of Cannabis Addiction on Human Emotions Processing: BOLD-RMRI Study
    - Manel Ben Fredj
  - University of Vermont, Reflection on Latest Trends in Research and Training in the Region
    - Richard Rawson, USA
  - University of Vermont, Trialing Neurocognitive Interventions During Detoxification
    - Dan Lubman, Australia

- **Hall F**
  - Protection, Anxiety and Stress Among Khat Chavers in Jazan Region, Kingdom of Saudi Arabia
    - Khat Use
    - Rashad Alsanosy, KSA
  - Depression, Anxiety and Stress Among Khat Chavers in Jazan Region, Kingdom of Saudi Arabia
    - Khat Use
    - Rashad Alsanosy, KSA
  - Effect of Khat Use on Antipsychotic Medications Among Schizophrenia Patients at Jazan Region, Kingdom of Saudi Arabia
    - Tahir Hakami, KSA
  - Measuring the Price of Elasticity of Khat Demand: A Cross-Sectional Study on Jazan Province
    - Maged El-Setouhy, KSA
  - Measuring the Income Elasticity of Khat Demand: A Cross-Sectional Study on Jazan Province
    - Kamaludin Sheikh, KSA

- **Hall G**
  - Updates on Khat Use in Jazan, Kingdom of Saudi Arabia
    - Rashad Alsanosy, KSA

### ISAM 2017 Schedule

- **Thursday, 26 October, 2017**
  - 12:15 - 12:45: Plenary Session 3 - Addiction in the Middle East: Status Update
  - 12:45 - 13:15: Plenary Session 4 - Mental Health Issues in the UAE
  - 13:15 - 14:15: Lunch Break - Poster Session
  - 14:15 - 16:15: EUROPAD Meeting (by invitation only)
  - 16:15 - 17:15: Plenary Session 5 - Stress and Addictions: Neurobiologic Interface
<table>
<thead>
<tr>
<th>Time</th>
<th>Session/Activity</th>
</tr>
</thead>
</table>
| 08:30 - 09:30| Plenary Session 6 - Global Trends and Challenges in Addiction Medicine: from Cannabis Regulations to the Workforce Development - Vladimir Poznyak, Switzerland  
Chair: WHO Representative / Tarek A. Gawad, UAE |
| 09:30 - 09:45| Coffee Break - Poster Session                                                     |
| 09:45 - 11:45| Plenary Session 6 - Global Trends and Challenges in Addiction Medicine: from Cannabis Regulations to the Workforce Development - Vladimir Poznyak, Switzerland  
Chair: WHO Representative / Tarek A. Gawad, UAE |

**Hall A**

- S10: Gilead Sponsored Symposium: Towards an Integrated Approach: Opioid Dependence Management and HCV Care  
  Chair: Hannu Alho, Finland  
  Co-Chair: Motaz Saad, Kuwait

- S11: HCV & opioid dependence. From epidemiology to action in the Middle East  
  Sheek-Hussein, UAE

- S12: Tolerance and Withdrawal in Gaming Disorder  
  Daniel King, Australia

- S13: The Comparison Between DSM-5 & ICD-11 in Reflecting the Severity of Gaming Disorder  
  Seung-Yup Lee, Korea

- S14: An integrated approach: clinical pathways, HCV treatment in people with complex needs  
  Markus Tan, UK

**Hall B**

- S11: Internet Gaming Disorder of DSM-5 and Gaming Disorder of Draft ICD-11: an Exploration for Refinement  
  Chair: Susumu Higuchi, Japan  
  Co-Chair: Vladimir Poznyak, Switzerland

- S12: Spirituality and Religion in Addiction Recovery  
  Marc Galanter, USA  
  Donald Kurth, USA

- S13: Twelve Step Spirituality-Based Recovery  
  Marc Galanter, USA

- S14: Application of Draft ICD-11 Diagnostic Guidelines for Gaming Disorder for Treatment Seeking Patients  
  Hideni Nakayama, Japan

**Hall C**

- S11: Spirituality and Therapeutic Experience  
  Gregory Bunt, USA

- S12: Spirituality/Religion in Substance Abuse Treatment: A Regional and Cultural Perspective  
  Ahmed Ali Yousef, UAE

- S13: Spirituality/Religion in Substance Abuse Treatment: A Modern Perspective  
  Donald Kurth, USA

- S14: Techniques of Transformation in Pentecostal Puerto Rican Addiction Ministries  
  Markus Tan, UK

**Hall D**

  Owen Bowden-Jones, UK

- S12: Recovering female substance dependence: psychiatric prole, addiction severity and challenges in Recovery  
  Rania Mamdouh, Egypt

- S13: Therapeutic Communities & Residential Treatment: A Modern Perspective  
  Donald Kurth, USA

- S14: An Exploration of the Prevalence of Social Network dysfunction and Loneliness in a sample of Patients with Comorbid Gaming Disorder and Gambling Disorder  
  Markus Tan, UK

**Hall E**

- S11: Therapeutic Communities Around the World  
  Chair: Gregory Bunt, USA  
  Co-Chair: Tarek Gawad, UAE

  Owen Bowden-Jones, UK

- S13: Therapeutic Communities in Delhi India  
  Ranjan Dhar, India

- S14: The Comparison Between DSM-5 & ICD-11 in Reflecting the Severity of Gaming Disorder  
  Seung-Yup Lee, Korea

- S15: Application of Draft ICD-11 Diagnostic Guidelines for Gaming Disorder for Treatment Seeking Patients  
  Hideni Nakayama, Japan

**Hall F**

- S11: Internet Addiction: Possible Correlations  
  Muhammad ElSalhy, Japan

- S12: Assessment of Smartphone Addiction Using Smartphone Usage Data and Machine Learning Technology  
  In Young Choi, Republic of Korea

- S13: Altered Gray Matter Volume in Internet Gaming Disorder in Comparison with Casual Gamers and Non-Gaming Users  
  Dai-Jin Kim, Republic of Korea

- S14: "The Validation of Implicit Association Test Measures for Smartphone and Internet Addiction in At-risk Children and Adolescents  
  Sang-Kyu Lee, Republic of Korea

**Hall G**

- S11: Internet Addiction: Possible Correlations  
  Muhammad ElSalhy, Japan

- S12: Assessment of Smartphone Addiction Using Smartphone Usage Data and Machine Learning Technology  
  In Young Choi, Republic of Korea

- S13: Altered Gray Matter Volume in Internet Gaming Disorder in Comparison with Casual Gamers and Non-Gaming Users  
  Dai-Jin Kim, Republic of Korea

- S14: "The Validation of Implicit Association Test Measures for Smartphone and Internet Addiction in At-risk Children and Adolescents  
  Sang-Kyu Lee, Republic of Korea

**Hall I**

- S11: ICD-11 Field Testing Focus Group Meeting  
  (by invitation only)
### Scientific Program

**Friday, 27 October, 2017**

**12:00 - 12:45**  
Plenary Session 7 - Brains, Hearts and Public Policy Toward Addiction  
Chair: Keith Humphreys, USA  
**Hall A**

**12:45 - 14:15**  
Lunch Break - Poster Session

**ISAM Education and Training Committee Meeting (by invitation only)**  
**Hall F**

**14:15 - 16:15**  
**Hall A**
- **S15**: Camurus Sponsored Symposium: Innovation & Opioid Dependence Care: Current Practice, Future Trends  
  Chair: Icro Maremmani, Italy  
  Co-Chair: Nicholas Lintzeris, Australia
- **S16**: Gambling Disorders & Co-Morbidities: Research Challenges  
  Chair: Nady El-Guebaly, Canada  
  Co-Chair: Mohamed Syed, UAE
- **S17**: Training Symposium  
  Chair: Shamili Wanigaratne, UAE  
  Co-Chair: Alex Baldacchino, UK
- **S18**: NIDA/NRC/ISAM Travel Award Winners  
  Chair: Steve Gust, USA
- **S19**: Tobacco Addiction Research in Women in the Middle East and North Africa  
  Chair: Mustafa al’Absi, USA  
  Co-Chair: Ahmed Yousif, UAE

**Hall B**  
- Medication assisted treatment: experience from research aiming to developing novel medications and in clinical practice.  
  Walter Ling, USA

**Hall C**  
- Current treatment in opioid dependence: evolution of current practice  
  Maurice Dematteis, France
- A Comparative PET Study in Pathological Gambling and Binge Eating  
  Hannu Alho, Finland
- Brain Awareness for Addiction Recovery Initiative (BARI): A Cartoon-based Psychoeducational Program for Addiction Recovery  
  Hamed Ekhtriari, USA
- The Virtual Doctor will See you Now: evaluation of a pilot elective in telemedicine for addiction trainees and role of tele-medical education in addiction fellowship  
  Kathleen Broad, Canada
- Cognitive Rehabilitation for Opioid Use Disorder  
  Tara Rezapour, Iran
- Correlates of Exposure to Passive Smoking During Pregnancy and Fetal Outcomes in Non-Smoking Pregnant Women in Tunisia: A Prospective Study.  
  Arwa Ben Salah

**Hall D**  
- Capacity Building: NRC Strategy for Education and Training and Workforce Development  
  Shamili Wanigaratne, UAE
- Training the Next Generation of Leaders: The Evolution of a Unique Multi-Disciplinary Addiction Training Programme  
  Amnabel Mead, Canada
- Cue-induced craving among adolescent inhalant users: A fMRI Study  
  Shobhit Jain, India
- White Matter Abnormalities in Opioid Dependence: A Controlled Study  
  Abhishek Ghosh, India
- Burden and Correlates of Cigarette Smoking Among Children Aged 12 to 17 Rears in UAE  
  Syed M Shah, UAE

**Hall E**  
- Women & Gambling Disorder: Latest Global Developments  
  Henrietta Bowden-Jones, UK
- Setting Limits: Gambling, Science and Public Policy  
  Thomas Babor, USA
- Training the Next Generation of Leaders: The Evolution of a Unique Multi-Disciplinary Addiction Training Programme  
  Jan Klimas, Canada
- Methods, Preliminary Results and Publication Impact of a Dedicated Addiction Clinician Scientist Research Fellowship  
  Areeb Shah, UAE
- White Matter Abnormalities in Opioid Dependence: A Controlled Study  
  Abhishek Ghosh, India

**Hall F**  
- Best practice in opioid dependence care: long term outcomes. What does clinical practice experience tell us?  
  Michael Soyka, Switzerland
- Research Challenges in Gambling and Comorbidities  
  Nady El-Guebaly, Canada
- Training the Next Generation of Leaders: The Evolution of a Unique Multi-Disciplinary Addiction Training Programme  
  Anabel Mead, Canada
- Cue-induced craving among adolescent inhalant users: A fMRI Study  
  Shobhit Jain, India
- White Matter Abnormalities in Opioid Dependence: A Controlled Study  
  Abhishek Ghosh, India
- Burden and Correlates of Cigarette Smoking Among Children Aged 12 to 17 Rears in UAE  
  Syed M Shah, UAE

**Hall G**  
- ISAM Education and Training Committee Meeting (by invitation only)
- IAR Journal Editorial Board Meeting (by invitation only)

**16:15 - 16:30**  
Coffee Break - Poster Session

**16:30 - 17:30**  
Plenary Session 8 - Addiction New Frontiers  
Chair: Ahmed El Kashef, UAE  
**Hall A**

**17:30 - 18:30**  
Future of OUD care. ISAM/EUROPAD 1st joint event. Innovative open discussion with global experts in addiction  
Chair: Hannu Alho, Finland  
Icro Maremmani, Italy  
Ivan Montoya, USA  
Keith Humphreys, USA  
**Hall E**
## SCIENTIFIC PROGRAM

### Saturday, 28 October, 2017

<table>
<thead>
<tr>
<th>Hall A</th>
<th>Hall B</th>
<th>Hall C</th>
<th>Hall D</th>
<th>Hall E</th>
<th>Hall F</th>
<th>Hall G</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>08:30 - 09:30</strong></td>
<td><strong>08:30 - 09:30</strong></td>
<td><strong>08:30 - 09:30</strong></td>
<td><strong>09:45 - 11:45</strong></td>
<td><strong>09:45 - 11:45</strong></td>
<td><strong>09:45 - 11:45</strong></td>
<td><strong>09:45 - 11:45</strong></td>
</tr>
<tr>
<td>Chair: Shamil Wanigaratne, UAE</td>
<td>Chair: Shamil Wanigaratne, UAE</td>
<td>Chair: Shamil Wanigaratne, UAE</td>
<td>Chair: Shamil Wanigaratne, UAE</td>
<td>Chair: Shamil Wanigaratne, UAE</td>
<td>Chair: Shamil Wanigaratne, UAE</td>
<td>Chair: Shamil Wanigaratne, UAE</td>
</tr>
<tr>
<td><strong>Hall A</strong></td>
<td><strong>Hall B</strong></td>
<td><strong>Hall C</strong></td>
<td><strong>Hall D</strong></td>
<td><strong>Hall E</strong></td>
<td><strong>Hall F</strong></td>
<td><strong>Hall G</strong></td>
</tr>
<tr>
<td>Chair: Marc Galanter, USA</td>
<td>Chair: Hamnu Alho, Finland</td>
<td>Chair: Seon-Wan Ki, Republic of Korea</td>
<td>Chair: Raju Hajala, Canada</td>
<td>Chair: Samya Al Maamari, UAE</td>
<td>Chair: Khalid Saeed, USA</td>
<td></td>
</tr>
<tr>
<td>USA History of Medicinal Cannabis and Cannabinoids</td>
<td>Extended Release Naltrexone - A Nine Month Follow-Up Study</td>
<td>Strategy for Substance Use Prevention Among School Students: an Insight from Moral Education Curricula</td>
<td>Developing Culturally Sensitive Cognitive Behavioral Therapy Program for treatment of Patients with Substance use disorders in Egypt: A pilot study</td>
<td>A Study of the Characteristics of A Clinical Populations of Substance Misusers in the UAE and an Exploration of Social Drift in this Population</td>
<td>Smoking Cessation Program in Indonesia from Hospital Service to Primary Health Care Service</td>
<td></td>
</tr>
<tr>
<td>Gregory Bunt, USA</td>
<td>Kristin Klemmetsby Solli, Norway</td>
<td>Layla Alhyas, UAE</td>
<td>Reham Aly, Egypt</td>
<td>Samya Al Maamari, UAE</td>
<td>Tribowo Tsuah Taing Ginting, Indonesia</td>
<td></td>
</tr>
<tr>
<td>Is Marijuana the New Big Tobacco? Lessons Learned from Legalization</td>
<td>Is Marijuana the New Big Tobacco? Lessons Learned from Legalization</td>
<td>Is Marijuana the New Big Tobacco? Lessons Learned from Legalization</td>
<td>Is Marijuana the New Big Tobacco? Lessons Learned from Legalization</td>
<td>Is Marijuana the New Big Tobacco? Lessons Learned from Legalization</td>
<td>Is Marijuana the New Big Tobacco? Lessons Learned from Legalization</td>
<td></td>
</tr>
<tr>
<td>Kevin Sabet, USA</td>
<td>Kevin Sabet, USA</td>
<td>Kevin Sabet, USA</td>
<td>Kevin Sabet, USA</td>
<td>Kevin Sabet, USA</td>
<td>Kevin Sabet, USA</td>
<td></td>
</tr>
<tr>
<td>USA Marijuana and Perspectives of Addiction Physicians Gregory Bunt, USA</td>
<td>USA Marijuana and Perspectives of Addiction Physicians Gregory Bunt, USA</td>
<td>USA Marijuana and Perspectives of Addiction Physicians Gregory Bunt, USA</td>
<td>USA Marijuana and Perspectives of Addiction Physicians Gregory Bunt, USA</td>
<td>USA Marijuana and Perspectives of Addiction Physicians Gregory Bunt, USA</td>
<td>USA Marijuana and Perspectives of Addiction Physicians Gregory Bunt, USA</td>
<td></td>
</tr>
<tr>
<td>Open-label, Multinational Phase III Study Evaluating Long-Term Safety and Efficacy of Weekly, and Monthly Subcutaneous Buprenorphine Depots (CAM2038) for Opioid Use Disorder Treatment Nicholas Lintzeris, Australia</td>
<td>Open-label, Multinational Phase III Study Evaluating Long-Term Safety and Efficacy of Weekly, and Monthly Subcutaneous Buprenorphine Depots (CAM2038) for Opioid Use Disorder Treatment Nicholas Lintzeris, Australia</td>
<td>Open-label, Multinational Phase III Study Evaluating Long-Term Safety and Efficacy of Weekly, and Monthly Subcutaneous Buprenorphine Depots (CAM2038) for Opioid Use Disorder Treatment Nicholas Lintzeris, Australia</td>
<td>Open-label, Multinational Phase III Study Evaluating Long-Term Safety and Efficacy of Weekly, and Monthly Subcutaneous Buprenorphine Depots (CAM2038) for Opioid Use Disorder Treatment Nicholas Lintzeris, Australia</td>
<td>Open-label, Multinational Phase III Study Evaluating Long-Term Safety and Efficacy of Weekly, and Monthly Subcutaneous Buprenorphine Depots (CAM2038) for Opioid Use Disorder Treatment Nicholas Lintzeris, Australia</td>
<td>Open-label, Multinational Phase III Study Evaluating Long-Term Safety and Efficacy of Weekly, and Monthly Subcutaneous Buprenorphine Depots (CAM2038) for Opioid Use Disorder Treatment Nicholas Lintzeris, Australia</td>
<td></td>
</tr>
<tr>
<td>Disulfiram: Why is it so Under-Used when it is Far More Effective than Naltrexone or Acamprosate? Colin Brewer, UK</td>
<td>Disulfiram: Why is it so Under-Used when it is Far More Effective than Naltrexone or Acamprosate? Colin Brewer, UK</td>
<td>Disulfiram: Why is it so Under-Used when it is Far More Effective than Naltrexone or Acamprosate? Colin Brewer, UK</td>
<td>Disulfiram: Why is it so Under-Used when it is Far More Effective than Naltrexone or Acamprosate? Colin Brewer, UK</td>
<td>Disulfiram: Why is it so Under-Used when it is Far More Effective than Naltrexone or Acamprosate? Colin Brewer, UK</td>
<td>Disulfiram: Why is it so Under-Used when it is Far More Effective than Naltrexone or Acamprosate? Colin Brewer, UK</td>
<td></td>
</tr>
<tr>
<td>Opioid Use Disorders in 'Medical Cannabis' Patients: Implications for Clinical Practice Nicholas Lintzeris, Australia</td>
<td>Opioid Use Disorders in 'Medical Cannabis' Patients: Implications for Clinical Practice Nicholas Lintzeris, Australia</td>
<td>Opioid Use Disorders in 'Medical Cannabis' Patients: Implications for Clinical Practice Nicholas Lintzeris, Australia</td>
<td>Opioid Use Disorders in 'Medical Cannabis' Patients: Implications for Clinical Practice Nicholas Lintzeris, Australia</td>
<td>Opioid Use Disorders in 'Medical Cannabis' Patients: Implications for Clinical Practice Nicholas Lintzeris, Australia</td>
<td>Opioid Use Disorders in 'Medical Cannabis' Patients: Implications for Clinical Practice Nicholas Lintzeris, Australia</td>
<td></td>
</tr>
<tr>
<td>Youth Curiosity Toward Drugs Implications to Preventive Drug Education Salina Samion, Singapore</td>
<td>Youth Curiosity Toward Drugs Implications to Preventive Drug Education Salina Samion, Singapore</td>
<td>Youth Curiosity Toward Drugs Implications to Preventive Drug Education Salina Samion, Singapore</td>
<td>Youth Curiosity Toward Drugs Implications to Preventive Drug Education Salina Samion, Singapore</td>
<td>Youth Curiosity Toward Drugs Implications to Preventive Drug Education Salina Samion, Singapore</td>
<td>Youth Curiosity Toward Drugs Implications to Preventive Drug Education Salina Samion, Singapore</td>
<td></td>
</tr>
<tr>
<td>Efficacy of Weekly and Monthly Depot Buprenorphine FluidCrystal® (CAM2038) versus Daily Sublingual Buprenorphine /Naloxone for Opioid use Disorder: Results from a Phase 3 Randomized, Double-Blind, Double-Dummy Mutisite Clinical Trial Michele Lofwall, USA</td>
<td>Efficacy of Weekly and Monthly Depot Buprenorphine FluidCrystal® (CAM2038) versus Daily Sublingual Buprenorphine FluidCrystal® (CAM2038) versus Daily Sublingual Buprenorphine /Naloxone for Opioid use Disorder: Results from a Phase 3 Randomized, Double-Blind, Double-Dummy Mutisite Clinical Trial Michele Lofwall, USA</td>
<td>Efficacy of Weekly and Monthly Depot Buprenorphine FluidCrystal® (CAM2038) versus Daily Sublingual Buprenorphine /Naloxone for Opioid use Disorder: Results from a Phase 3 Randomized, Double-Blind, Double-Dummy Mutisite Clinical Trial Michele Lofwall, USA</td>
<td>Efficacy of Weekly and Monthly Depot Buprenorphine FluidCrystal® (CAM2038) versus Daily Sublingual Buprenorphine /Naloxone for Opioid use Disorder: Results from a Phase 3 Randomized, Double-Blind, Double-Dummy Mutisite Clinical Trial Michele Lofwall, USA</td>
<td>Efficacy of Weekly and Monthly Depot Buprenorphine FluidCrystal® (CAM2038) versus Daily Sublingual Buprenorphine /Naloxone for Opioid use Disorder: Results from a Phase 3 Randomized, Double-Blind, Double-Dummy Mutisite Clinical Trial Michele Lofwall, USA</td>
<td>Efficacy of Weekly and Monthly Depot Buprenorphine FluidCrystal® (CAM2038) versus Daily Sublingual Buprenorphine /Naloxone for Opioid use Disorder: Results from a Phase 3 Randomized, Double-Blind, Double-Dummy Mutisite Clinical Trial Michele Lofwall, USA</td>
<td></td>
</tr>
</tbody>
</table>
### SCIENTIFIC PROGRAM

**Saturday, 28 October, 2017**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Hall A</th>
<th>Hall B</th>
<th>Hall C</th>
<th>Hall D</th>
<th>Hall E</th>
<th>Hall F</th>
<th>Hall G</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:00 - 12:45</td>
<td>Plenary Session 10 - Behavioral Addictions: Scientific Update</td>
<td>S26: Late Breaking Session</td>
<td>S27: Special Populations&lt;br&gt;Chair: Gabrielle Welle-Strand, Norway&lt;br&gt;Co-Chair: Naseeba Ozaibi, UAE</td>
<td>S28: Patterns of Tobacco Use in the Emirate of Abu Dhabi and rates of misclassification: Results of a pilot study&lt;br&gt;Chair: Mansour Shawky, UAE</td>
<td>S29: Recent Research Findings on Tobacco Addiction: Regional Patterns, Challenges &amp; Consequences&lt;br&gt;Chair: Mustafa Al'Abbsi, USA&lt;br&gt;Co-Chair: Scott Sherman, USA</td>
<td><strong>Young Career Psychiatrists Meeting (by invitation only)</strong></td>
<td><strong>External Funding Committee Meeting (by invitation only)</strong></td>
<td>ISAM General Assembly Meeting&lt;br&gt;Hall A&lt;br&gt;ME6: So you want to Publish a Primer?&lt;br&gt;Nady El-Guebaly, Canada&lt;br&gt;Thomas Babor, USA</td>
</tr>
<tr>
<td>12:45 - 14:15</td>
<td>Lunch Break - Poster Session</td>
<td>ISAM General Assembly Meeting</td>
<td>Diagnosis and Treatment of HCV Infection: A Tool of Engagement for People who Inject Drugs (PWID) Through Community Pop-Up Clinics (CPCs)&lt;br&gt;Arshia Alimohammadi, Canada</td>
<td>How do Mothers/Parents in Opioid Maintenance Treatment (OMT) do 8-12 Years After their Child was Born?&lt;br&gt;Gabrielle Welle-Strand, Norway</td>
<td>How do Motherrs/Parents in Opioid Maintenance Treatment (OMT) do 8-12 Years After their Child was Born?&lt;br&gt;Gabrielle Welle-Strand, Norway</td>
<td>Isacopo Belcari, Italy</td>
<td><strong>Hall F</strong>&lt;br&gt;Fall B&lt;br&gt;<strong>Hall G</strong>&lt;br&gt;Young Career Psychiatrists Meeting (by invitation only)</td>
<td>ISAM General Assembly Meeting&lt;br&gt;Hall A&lt;br&gt;ME6: So you want to Publish a Primer?&lt;br&gt;Nady El-Guebaly, Canada&lt;br&gt;Thomas Babor, USA</td>
</tr>
<tr>
<td>14:15 - 16:15</td>
<td>ISAM General Assembly Meeting</td>
<td>Evaluating the Impact of Prescribed Versus Non-Prescribed Benzodiazepine Use in Opioid Substitution Therapy&lt;br&gt;David C. Marsh, USA</td>
<td>Predictors for Completion of Detoxification Program in Adolescents Attending a Detoxification Facility&lt;br&gt;Wole Akosile, Australia</td>
<td>Intellectual Functioning of School-Aged Children&lt;br&gt;Prenatally Exposed to OMT-Medications&lt;br&gt;Monica Sarfi, Norway</td>
<td>Specific Psychopathology of Addiction&lt;br&gt;Angelo GI Maremmani, Italy</td>
<td>Psychological/psychiatric&lt;br&gt;Precurors of Addiction&lt;br&gt;Arshia Alimohammadi, Canada</td>
<td><strong>Hall F</strong>&lt;br&gt;Fall B&lt;br&gt;<strong>Hall G</strong>&lt;br&gt;Young Career Psychiatrists Meeting (by invitation only)</td>
<td><strong>Hall G</strong>&lt;br&gt;Young Career Psychiatrists Meeting (by invitation only)</td>
</tr>
<tr>
<td>14:15 - 16:15</td>
<td>ISAM General Assembly Meeting</td>
<td>The Reinforcing and Subjective Effects of Opioids in Opioid Users With and Without Chronic Pain Who are Maintained on Sublingual Buprenorphine&lt;br&gt;Sandra Comer, USA</td>
<td>The Reinforcing and Subjective Effects of Opioids in Opioid Users With and Without Chronic Pain Who are Maintained on Sublingual Buprenorphine&lt;br&gt;Sandra Comer, USA</td>
<td>The Reinforcing and Subjective Effects of Opioids in Opioid Users With and Without Chronic Pain Who are Maintained on Sublingual Buprenorphine&lt;br&gt;Sandra Comer, USA</td>
<td>The Reinforcing and Subjective Effects of Opioids in Opioid Users With and Without Chronic Pain Who are Maintained on Sublingual Buprenorphine&lt;br&gt;Sandra Comer, USA</td>
<td>The Reinforcing and Subjective Effects of Opioids in Opioid Users With and Without Chronic Pain Who are Maintained on Sublingual Buprenorphine&lt;br&gt;Sandra Comer, USA</td>
<td>The Reinforcing and Subjective Effects of Opioids in Opioid Users With and Without Chronic Pain Who are Maintained on Sublingual Buprenorphine&lt;br&gt;Sandra Comer, USA</td>
<td>The Reinforcing and Subjective Effects of Opioids in Opioid Users With and Without Chronic Pain Who are Maintained on Sublingual Buprenorphine&lt;br&gt;Sandra Comer, USA</td>
</tr>
<tr>
<td>14:15 - 16:15</td>
<td>ISAM General Assembly Meeting</td>
<td>HCV Reinfection and Injection Risk Behaviour Following Elbasvir/Grazoprevir Treatment in Participants on Opioid Agonist Therapy, Co-Star Three-Year Follow-Up Study&lt;br&gt;Brian Conway, Canada</td>
<td>HCV Reinfection and Injection Risk Behaviour Following Elbasvir/Grazoprevir Treatment in Participants on Opioid Agonist Therapy, Co-Star Three-Year Follow-Up Study&lt;br&gt;Brian Conway, Canada</td>
<td>HCV Reinfection and Injection Risk Behaviour Following Elbasvir/Grazoprevir Treatment in Participants on Opioid Agonist Therapy, Co-Star Three-Year Follow-Up Study&lt;br&gt;Brian Conway, Canada</td>
<td>HCV Reinfection and Injection Risk Behaviour Following Elbasvir/Grazoprevir Treatment in Participants on Opioid Agonist Therapy, Co-Star Three-Year Follow-Up Study&lt;br&gt;Brian Conway, Canada</td>
<td>HCV Reinfection and Injection Risk Behaviour Following Elbasvir/Grazoprevir Treatment in Participants on Opioid Agonist Therapy, Co-Star Three-Year Follow-Up Study&lt;br&gt;Brian Conway, Canada</td>
<td>HCV Reinfection and Injection Risk Behaviour Following Elbasvir/Grazoprevir Treatment in Participants on Opioid Agonist Therapy, Co-Star Three-Year Follow-Up Study&lt;br&gt;Brian Conway, Canada</td>
<td>HCV Reinfection and Injection Risk Behaviour Following Elbasvir/Grazoprevir Treatment in Participants on Opioid Agonist Therapy, Co-Star Three-Year Follow-Up Study&lt;br&gt;Brian Conway, Canada</td>
</tr>
<tr>
<td>16:15 - 16:30</td>
<td>Coffee Break - Poster Session</td>
<td>ISAM General Assembly Meeting</td>
<td>Evaluating the Impact of Prescribed Versus Non-Prescribed Benzodiazepine Use in Opioid Substitution Therapy&lt;br&gt;David C. Marsh, USA</td>
<td>Evaluating the Impact of Prescribed Versus Non-Prescribed Benzodiazepine Use in Opioid Substitution Therapy&lt;br&gt;David C. Marsh, USA</td>
<td>Evaluating the Impact of Prescribed Versus Non-Prescribed Benzodiazepine Use in Opioid Substitution Therapy&lt;br&gt;David C. Marsh, USA</td>
<td>Evaluating the Impact of Prescribed Versus Non-Prescribed Benzodiazepine Use in Opioid Substitution Therapy&lt;br&gt;David C. Marsh, USA</td>
<td>Evaluating the Impact of Prescribed Versus Non-Prescribed Benzodiazepine Use in Opioid Substitution Therapy&lt;br&gt;David C. Marsh, USA</td>
<td>Evaluating the Impact of Prescribed Versus Non-Prescribed Benzodiazepine Use in Opioid Substitution Therapy&lt;br&gt;David C. Marsh, USA</td>
</tr>
<tr>
<td>16:30 - 17:30</td>
<td>Plenary Session 11 - Novel Psychoactive Substances: The Emerging Face of Drug Abuse</td>
<td>ISAM General Assembly Meeting</td>
<td>Evaluating the Impact of Prescribed Versus Non-Prescribed Benzodiazepine Use in Opioid Substitution Therapy&lt;br&gt;David C. Marsh, USA</td>
<td>Evaluating the Impact of Prescribed Versus Non-Prescribed Benzodiazepine Use in Opioid Substitution Therapy&lt;br&gt;David C. Marsh, USA</td>
<td>Evaluating the Impact of Prescribed Versus Non-Prescribed Benzodiazepine Use in Opioid Substitution Therapy&lt;br&gt;David C. Marsh, USA</td>
<td>Evaluating the Impact of Prescribed Versus Non-Prescribed Benzodiazepine Use in Opioid Substitution Therapy&lt;br&gt;David C. Marsh, USA</td>
<td>Evaluating the Impact of Prescribed Versus Non-Prescribed Benzodiazepine Use in Opioid Substitution Therapy&lt;br&gt;David C. Marsh, USA</td>
<td>Evaluating the Impact of Prescribed Versus Non-Prescribed Benzodiazepine Use in Opioid Substitution Therapy&lt;br&gt;David C. Marsh, USA</td>
</tr>
<tr>
<td>19:30 - 22:00</td>
<td>Gala Dinner (by invitation)</td>
<td>ISAM General Assembly Meeting</td>
<td>Evaluating the Impact of Prescribed Versus Non-Prescribed Benzodiazepine Use in Opioid Substitution Therapy&lt;br&gt;David C. Marsh, USA</td>
<td>Evaluating the Impact of Prescribed Versus Non-Prescribed Benzodiazepine Use in Opioid Substitution Therapy&lt;br&gt;David C. Marsh, USA</td>
<td>Evaluating the Impact of Prescribed Versus Non-Prescribed Benzodiazepine Use in Opioid Substitution Therapy&lt;br&gt;David C. Marsh, USA</td>
<td>Evaluating the Impact of Prescribed Versus Non-Prescribed Benzodiazepine Use in Opioid Substitution Therapy&lt;br&gt;David C. Marsh, USA</td>
<td>Evaluating the Impact of Prescribed Versus Non-Prescribed Benzodiazepine Use in Opioid Substitution Therapy&lt;br&gt;David C. Marsh, USA</td>
<td>Evaluating the Impact of Prescribed Versus Non-Prescribed Benzodiazepine Use in Opioid Substitution Therapy&lt;br&gt;David C. Marsh, USA</td>
</tr>
<tr>
<td>Time</td>
<td>Event</td>
<td>Hall</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>--------------</td>
<td>----------------------------------------------------------------------</td>
<td>---------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>08:30 - 09:30</td>
<td>Plenary Session 12 - Application of Drug Court Principles to other Courts – The San Diego Experiment – Desiree Bruce-Lyle, USA</td>
<td>Hall A</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:30 - 09:45</td>
<td>Coffee Break - Poster Session</td>
<td>Hall A</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:45 - 11:45</td>
<td>Delivering Rehabilitation and Recovery in Prisons</td>
<td>Hall A</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00 - 12:30</td>
<td>Plenary Session 13 - Drug Use, Drug Control and Human Rights: Issues Raise at UNGASS an Satellite Meetings: How should ISAM respond - Norman Wetterau, USA</td>
<td>Hall A</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Plenary Session 14 - Assessment of situation and response to injecting drug use and its harms in the Middle East and North Africa - Afarin Rahimi-Movaghar, Iran</td>
<td>Hall A</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:00 - 13:30</td>
<td>Closing Ceremony</td>
<td>Hall A</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Hall A**

**S31:** Drug Courts 2  
Chair: Igor Koutsenok  
Co-Chair: Judge, UAE

**S32:** Harm Reduction and Recovery  
Chair: Candice Dwyer, Canada

**S33:** Policy and Services  
Chair: Thomas Babor, USA  
Co-Chair: Ali Marzoqi, UAE

**S34:** Hot Topics in Drugs of Abuse Toxicology  
Chair: Abuelgasim Elrasheed, UAE  
Co-Chair: Asma Alwahdi

**S35:** Prison Treatment  
Chair: Michael Trace, UK  
Co-Chair: Ahmed Yousif, UAE

**Panel/Presentation Political Invites**

Translating Research into Practice to Increase the Drug Demand Reduction Workforce  
Charlotte Sisson, USA

**Forensic Legal Issues in Addiction Medicine**  
Larry Westreich

**Criminal Justice Reform**  
Gregory Bunt, USA

**Criminal Justice Treatment & the Therapeutic Community**  
Seep Varma, India

**Biological Tools in Addiction Treatment**  
Basma Al Harthy, KSA

**Pharmacology and Toxicology of Classical Drugs of Abuse**  
Hans Maurer, Germany

**Promoting Treatment Within the Criminal Justice System**  
Charlotte Sisson, USA

**Delivering Rehabilitation and Recovery in Prisons Experience and Research from the UK**  
Michael Trace, UK

**Patterns of Drug Abuse Amongst NRC Patients Abuelgasim Elrasheed, UAE**

**Oral Fluid Testing for Cannabinoids**  
Marilyn Huestis, USA

**New Psychoactive Substances**  
Simon Elliott, UK

**Overview of the Drug Court Model**  
Igor Koutsenok, USA

**The Effects of extract of Black Sticky Rice with Giant Embryo on the Alcohol Cravings in Korean Social Drinkers During Twelve Weeks**  
Sung-Gon Kim, South Korea

**Actual prevalence of HCV HBV and HIV among Drug Users Attending Harm Reduction Programs in Bucharest**  
Adrian Octavian Abagiu, Romania

**Treatment to Address Mental Health Disorders in Latinos & Analysis of the Predictive Factors that Interfere with the Level of Functioning**  
Milton Cesar Sanchez, USA

**New Psychoactive Substances**  
Simon Elliott, UK

**Effects of harm reduction approach on individuals with alcohol use disorder in Japan**  
Yousek Yumoto, Japan

**Public Health Approach as the Basis for Addiction Policy, the Swiss Report on the Challenge of Addiction**  
Riaz Khan, Switzerland

**Impact of Pharmacogonomics and Drug/Drug interaction on Toxicological Case Interpretation**  
Hans Maurer, Germany

**Pilot of a computer-delivered motivation programme for drug inmates in Singapore Prison Services**  
Quinten Lee, Singapore